| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $195,797,115 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA265050 | New Therapuetics for Pancreatic Cancer | 001 | 4 | NIH | 6/9/2025 | $598,329 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK098468 | Role of Circadian Misalignment in Beta-cell Failure in Type 2 Diabetes | 001 | 14 | NIH | 6/30/2025 | $516,603 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI170535 | Characterizing the role of CSDE1 as a critical co-factor for VSV replication. | 000 | 3 | NIH | 2/12/2025 | $391,395 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK122948 | Lipotoxicity and Liver Inflammation | 001 | 6 | NIH | 2/28/2025 | $525,565 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG044615 | Respiratory Control in Old Age | 002 | 13 | NIH | 7/31/2025 | $602,958 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA283663 | Next-Generation Whole-Body MRI for Detection and Assessment of Therapy Response in Bone Lesions | 002 | 3 | NIH | 6/18/2025 | $582,617 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB036541 | A Dynamic Patient Data Library and Virtual Imaging Trial Platform for Training and Evaluating AI-based Algorithms in CT Imaging | 000 | 1 | NIH | 7/23/2025 | $641,063 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK137231 | Engineering microcapsules for scalable differentiation of human pluripotent stem cells into hepatocytes | 000 | 2 | NIH | 2/20/2025 | $500,141 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03OD039975 | Rare variant analysis integrating large public DNA sequencing controls and gene expression data for discovering novel predisposition genes of orofacial clefts | 000 | 1 | NIH | 6/10/2025 | $1 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03OD039975 | Rare variant analysis integrating large public DNA sequencing controls and gene expression data for discovering novel predisposition genes of orofacial clefts | 000 | 1 | NIH | 6/10/2025 | $320,799 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F32DK145067 | The role of sympathetic signaling in inflammation-induced colon dysfunction and recovery | 001 | 1 | NIH | 7/31/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA271410 | Mayo Clinic Center for Clinical Proteomics | 001 | 4 | NIH | 7/29/2025 | $1,115,210 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F32DK145067 | The role of sympathetic signaling in inflammation-induced colon dysfunction and recovery | 000 | 1 | NIH | 7/31/2025 | $75,520 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG050603 | Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study | 001 | 10 | NIH | 6/10/2025 | $63,472 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG050603 | Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study | 000 | 10 | NIH | 3/18/2025 | $714,049 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R33AT012185 | MRI-based quantitative characterization of impaired myofascial interface properties in myofascial pain syndrome | 000 | 2 | NIH | 8/12/2025 | $1,578,672 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK137231 | Engineering microcapsules for scalable differentiation of human pluripotent stem cells into hepatocytes | 001 | 2 | NIH | 6/18/2025 | $55,572 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL164416 | Targeting Immune-Responsive Gene 1 (Irg1) and Itaconate for Cardioprotection of the Donor Heart for Transplantation | 002 | 4 | NIH | 7/29/2025 | $647,639 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 001 | 2 | NIH | 5/22/2025 | $18,863 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 000 | 2 | NIH | 3/20/2025 | $169,773 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U10CA180882 | Alliance Statistics and Data Management Center | 001 | 11 | NIH | 7/10/2025 | $3,190,073 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U10CA180882 | Alliance Statistics and Data Management Center | 000 | 11 | NIH | 3/14/2025 | $4,779,823 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 001 | 3 | NIH | 5/22/2025 | $67,152 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 000 | 3 | NIH | 3/19/2025 | $604,359 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 001 | 4 | NIH | 6/25/2025 | $62,245 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 000 | 4 | NIH | 3/17/2025 | $560,204 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03CA292132 | Targeting Ferroptosis in Cholangiocarcinoma with siRNA-based Nanovesicles | 000 | 1 | NIH | 7/23/2025 | $161,400 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 001 | 4 | NIH | 6/17/2025 | $26,076 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 000 | 4 | NIH | 3/6/2025 | $293,355 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F30CA294722 | DNA aptamers as tools for toxin delivery to glioblastoma | 001 | 1 | NIH | 7/10/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F30CA294722 | DNA aptamers as tools for toxin delivery to glioblastoma | 000 | 1 | NIH | 7/10/2025 | $49,738 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL167796 | Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis | 001 | 2 | NIH | 7/16/2025 | $58,902 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL167796 | Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis | 000 | 2 | NIH | 3/5/2025 | $530,118 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD016230 | Rural Patient Risks and Exposures for Diabetes ConTrol (Rural PREDICT) | 002 | 5 | NIH | 4/15/2025 | -$11,002 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DC022228 | High-resolution in vivo imaging of inner ear using photon-counting-detector computed tomography and artificial intelligence | 000 | 1 | NIH | 7/1/2025 | $711,342 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD016230 | Rural Patient Risks and Exposures for Diabetes ConTrol (Rural PREDICT) | 000 | 5 | NIH | 2/18/2025 | $146,896 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271486 | Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis | 001 | 4 | NIH | 6/10/2025 | $41,397 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA271486 | Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis | 000 | 4 | NIH | 2/28/2025 | $372,578 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB036987 | AI-assisted quantitative photon-counting-detector CT imaging for cytogenetic risk prediction and treatment response in multiple myeloma | 000 | 1 | NIH | 3/19/2025 | $546,874 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276851 | Glioma intelligence from behind enemy lines | 001 | 3 | NIH | 5/29/2025 | $52,545 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA276851 | Glioma intelligence from behind enemy lines | 000 | 3 | NIH | 3/3/2025 | $472,910 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG081584 | Biophysically inspired mechanical biomarkers of normal pressure hydrocephalus | 001 | 2 | NIH | 6/10/2025 | $32,280 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG081584 | Biophysically inspired mechanical biomarkers of normal pressure hydrocephalus | 000 | 2 | NIH | 3/20/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD019644 | Screening Mammography: Early Breast Cancer Detection for All at Risk | 001 | 2 | NIH | 7/29/2025 | $155,520 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | OT2OD039849 | All of Us Biobank | 000 | 1 | NIH | 7/22/2025 | $80,770 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | OT2OD039849 | All of Us Biobank | 000 | 1 | NIH | 7/22/2025 | $13,400,000 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | OT2OD039849 | All of Us Biobank | 000 | 1 | NIH | 7/22/2025 | $5,751,974 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL176555 | Discovering aging-associated genetic modifiers and therapies for anthracycline-induced cardiotoxicity | 000 | 1 | NIH | 7/23/2025 | $680,583 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG093316 | Multiomic analysis of downstream molecular effect of teloemre length in individual chromosome arms | 000 | 1 | NIH | 7/29/2025 | $441,100 |
|
